Krebs Biochemicals board meeting scheduled for May 21, 2026 to approve audited Q4 and FY26 financial results.
Trading window closure for insiders effective from March 31, 2026 until 48 hours after results declaration.
Regulatory intimation filed under SEBI Listing Regulations Regulation 29 for board meeting disclosure.